Q1 NEWS LETTER SPRING 2026

ARHI
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT

@arhiusa | Advanced Research for Health Improvement
1172 Goodlette Frank Road North, Suite # 201. Naples, Florida 34102
(239) 230-2021 | info@arhiusa.com | www.arhiusa.com

ACHIEVEMENTS



ARHI and Principal Investigator Dr. Julian J. Javier contribute to groundbreaking STEM CELL CLINICAL TRIAL FOR AGING FRAILTY PUBLISHED IN CELL STEM CELL

ARHI announced the publication of a **Phase 2b clinical trial in Cell Stem Cell evaluating laromestrocel**, an investigational stem cell therapy for age-related frailty. Led in part by **Principal Investigator Dr. Julian J. Javier**, the randomized, placebo-controlled study in 148 older adults demonstrated meaningful improvements in physical endurance, including increased 6-minute walk distance, along with enhanced patient-reported function.

The findings also suggest a potential biological mechanism tied to treatment response, **marking a significant step forward in regenerative medicine for frailty.** This milestone reinforces ARHI's commitment to advancing innovative, evidence-based therapies aimed at improving health outcomes in aging populations.

CARDAMYST™ now approved SELF-ADMINISTERED TREATMENT

Milestone Pharmaceuticals announced the U.S. availability of CARDAMYST™ (etripamil) nasal spray, marking the commercial launch of its first approved product. **The therapy is now accessible through retail pharmacies and is designed as a self-administered, rapid-response treatment for adults** experiencing episodes of paroxysmal supraventricular tachycardia (PSVT), a type of abnormal heart rhythm.

CARDAMYST represents **the first new FDA-approved treatment for PSVT in over 30 years** and offers patients the ability to manage episodes outside of emergency settings. **The launch is supported by a national commercial rollout and patient assistance programs,** including reimbursement support and potential copay reductions, aimed at improving access and affordability.

ACTIVITIES

FEBRUARY 23-24 — Eli Lilly GZMG Investigator Engagement Meeting to Advance Opioid Use Disorder Clinical Research

ARHI representatives, **Principal Investigator Dr. Leonard Lado and Clinical Trials Manager Juan C. Ramos, M.S.,** participated in the **Eli Lilly GZMG Investigator Engagement Meeting** held March 23–24, 2026, in Atlanta, GA. The meeting brought together investigators, research teams, and sponsor representatives to discuss the development of an upcoming clinical trial focused on **Opioid Use Disorder (OUD)**, including trial design, operations, and participant engagement strategies.

Through this collaboration, ARHI gained valuable insights into protocol development, regulatory considerations, and multi-site coordination, r**einforcing its commitment to research excellence and patient-centered clinical trials.** ARHI continues to expand its role in advancing innovative, multi-center research aimed at addressing high-impact health conditions.

MARCH 31st — The Importance of Diversity and Inclusion in Clinical Trials: Current Trends and Enrolling Trials







ARHI hosted a community-centered **event at The Social Hampton in Naples focused on promoting diversity and inclusion in clinical trials.** The event brought together research professionals, healthcare providers, and community advocates to discuss ways to improve representation and expand access to innovative treatments.

Dr. Perez underscored the importance of diverse participation in developing safe and effective therapies for all populations, while addressing key barriers such as low awareness, mistrust, and limited access.

Attendees explored practical strategies to enhance inclusion, including **community engagement, culturally competent communication, multilingual outreach, and stronger partnerships with local providers.** The program also featured presentations of actively enrolling clinical trials by **Dr. Leonard Lado, Dr. Tracey Roth, and Dr. Shahzaib Mirza,** along with contributions from the Nurse Practitioner Council of Naples. ARHI reaffirmed its commitment to advancing inclusive research and closed the event with a call to action to prioritize diversity in future studies.

NEW STUDIES OPENED

In Q3, ARHI successfully launched **new clinical trials in Naples, Florida,** strengthening our role as a trusted provider of advanced medical research and accessible patient care in Southwest Florida.

Community Impact:
Free, advanced medical oversight for eligible residents.
Compensation per participant to help cover time and travel.
Expanded outreach in Naples and neighboring communities, including Immokalee, Bonita Springs, Marco Island, and Fort Myers.

Strategic Impact:
These trials reaffirm our **commitment to delivering patient-focused innovation,** creating local health benefits while contributing valuable data to **shape future global treatments.**

Outlook:
We expect to build on this momentum by expanding outreach and strengthening partnerships with local healthcare providers, **ensuring that more patients can benefit from new care options and contribute to medical breakthroughs.**



Obesity and Osteoarthritis of the Knee Clinical Study

Research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose weight and reduce pain.

Opioid Abuse Disorder (OUD) Clinical Study

A study to evaluate the efficacy and safety of brenipatide as adjunctive treatment to buprenorphine with or without naloxone in early recovery of participants with opioid use.

Prevention of Major Adverse Cardiovascular Events Clinical Trial

A Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a)

ACTIVE STUDIES UPDATES

Our site successfully conducted 155 patient visits from January through March 2026. All of our coordinators: Julian, Maria Claudia, Ismery, and Lesky have worked diligently to achieve the goals set for all ongoing trials at this site. Please join the management team in congratulating them and recognizing their hard work and dedication!

Chronic Obstructive Pulmonary Disease
(COPD)
Enrolling Now!

COPD on the Heart
(COPD)
Enrolling Now!

Atherosclerotic Cardiovascular Disease
(ASCVD)
Enrolling Now!

ARHI
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT
For more info:
@arhiusa | Advanced Research for Health Improvement
1172 Goodlette Frank Road North, Suite # 201. Naples, Florida 34102
(239) 230-2021 | info@arhiusa.com | www.arhiusa.com